PROMOTER METHYLATION AND PTEN GENE SILENCING IN CERVICAL SQUAMOUS CELL CARCINOMA FROM NORTH INDIAN POPULATION

Biochemical and Cellular Archives

Volumn 11, Issue 1, 2011, Pages 33-39

  Kumar, Birendra ^a   Yadav, M M A ^a   Yadav, P R ^a   Mandal, A K ^a  

^a Department of Biosciences   (India)

Author keywords

Cervical Squamous Cell Carcinoma; Immunohistochemistry; Promoter Methylation; PTEN; Tumor suppressor gene

Indexed keywords

EID: 84555188380     PISSN: 09725075     EISSN: 09761772     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Parkin D, Bray F, Ferlay J and Pisani P (2002) Global cancer statistics. 2002. CA
2. Sankaranaryanan R, Buduk A M and Rajkumar R (2001) Effective Screening Programmes for Cervical Cancer in low- and middle-income developing countries. Bull World Health Organ 79,
3. Ferlay J, Bray F, Pisani P and Parkin D M (2002) GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. In IARC Cancer Base No. 5, version 2.0 IARC Press, Lyon; (2004).
4. Walboomers J M, Jacobs M V, Manos M M, Bosch F X, Kummer J A and Shah K V (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189, 12–19.
5. Lazo P A (1999) The molecular genetics of cervical carcinoma. Br. J. Cancer 80, 2008–18.
6. Li J, Yen C and Liaw D (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947.
7. Steck P A, Pershouse M A and Jasser S A (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15, 356-362.
8. Maehama T and Dixon J E (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. biol Chem. 273, 13375- 13378.
9. Wu X, Senechal K, Neshat M S, Whang Y E and Sawyers C L (1998) The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3- kinase/Akt pathway. Proc. Natl. Acad. Sci. USA 95, 15587-15591.
10. Rasheed B K, Stenzel T T, McLendon R E, Parsons R, Friedman A H, Friedman H S, Bigner D D and Bigner S H (1997) PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 57, 4187-4190.
11. Guldberg P, Straten P, BirckA,Ahrenkiel V, Kirkin A F and Zeuthen J (1997) Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57, 3660-3663.
12. Gray I C, Phillips S M, Lee S J, Neoptolemos J P, Weissenbach J and Spurr N K (1995). Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res. 55, 4800-4803.
13. Suzuki H, Freije D, Nusskern D R, Okami K, Cairns P, Sidransky D, Isaacs W B and Bova G S (1998). Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res., 58, 204-209.
14. Kong D, Suzuki A,Zou T T, SakuradaA, Kemp L W, Wakatsuki S, Yokoyama T, Yamakawa H, Furukawa T,Sato M, Ohuchi N, Sato S, Yin J, Wang S,Abraham J M, Souza R F, Smolinski K N, Meltzer S J and Horii A (1997). PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 17,143-144.
15. Risinger J I, Hayes K, BerchuckA and Barrett J C (1997). PTEN/MMAC1 Mutations in endometrial cancers. Cancer Res, 57, 4736-4738.
16. Tashiro H, Blazes M S, Wu R, Cho K R, Bose S, Wang S I, Li J, Parsons R and Ellenson L H(1997). Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res, 57, 3935-3940.
17. Rhei E, Kang L, Bogomolniy F, Federici M G, Borgen P I, Boyd J (1997). Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res, 57, 3657-3659.
18. Zhang L, Liu T, Liu H, Gao J and Gu C (2000) Loss and inactivation of PTEN/MMAC1/TEP1 gene in lung cancer. Zhonghua Bing Li Xue Za Zhi, 29, 85-88.
19. Mitra A B, Murty V V V S, Li R G, Pratap M, Luthra U K and Chaganti R S K (1994). Allelotype analysis of cervical carcinoma. Cancer Res 54, 4481-4487.
20. Miayani K, Furugen Y, Matsumoto T, Iwabuchi K, Hirose S, Kinoshita K and Fujii H (2004) Loss of heterozygosity analysis in uterine cervical adenocarcinomas. Gynecol. Oncol., 94, 115-120.
21. Kurose K, Zhou X P,Araki T and Eng C (2000) Biallelic inactivating mutations and an occult germline mutation of PTEN in primary cervical carcinomas. Genes Chromosomes Cancer, 29,166-172.
22. Whang Y E, Wu X, Suzuki H, Reiter R E, Tran C, Vessella R L, Said J W, Isaacs W B and Sawyers C L (1998). Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA, 95, 5246–5250.
23. Salvesen H B, MacDonald N, Ryan A, Jacobs I J, Lynch E D, Akslen L A and Das S (2001) PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int. J. Cancer,91, 22–26.
24. Zhou X P, Gimm O, Hampel H, Niemann T, Walker M J and Eng C (2000). Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am. J. Pathol., 157,1123–1128.
25. Herman J G (1999) Hypermethylation of tumor suppressor genes in cancer. Semin. Cancer Biol. 9, 359–367.
26. Merlo A, Herman J G, Mao L, Lee D J, Gabrielson E, Burger P C, Baylin S B and Sidransky D (1995). 59 CpG island methylation is associated with transcriptional silencing of thetumor suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1,686—692.
27. Herman J G, Latif F, Weng Y, Lerman M I, Zbar B, Liu S, Samid D, Duan D R, Gnarra J R, LinehanW M and Baylin S B (1994). Silencing of the VHL tumor-suppressorgene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA 91, 9700–9704.
28. Herman J G, Umar A, Polyak K, Graff J R, Ahuja N, Issa J P, Markowitz S, Wilson J K V, Hamilton S R, Kinzler K W, Kane M F, Kolodner R D, Volgelstein B, Kunkel T A and Baylin S B (1998). Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA, 95, 6870–6875.
29. Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, Peinado M A, Gonzalez S, Tarafa G, Sidransky D, Meltzer S J, Baylin S B and Herman J G (2000). Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 60, 4366–4371.
30. Graff J R, Herman J G, Lapidus R G, Chopra H, Xu R, Jarrard D F, Isaacs W B, Pitha P M, Davidson N E and Baylin S B (1995). E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res., 55, 5195– 5199, 1995.
31. Kang Y H, Lee H S and Kim W H(2002) Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest,82, 285– 291.
32. SoriaJ C, Lee H Y, Lee J I, Wang L, Issa J P, Kemp B L, Liu D D, Kurie J M, Mao L and Khuri F R (2002). Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res, 8,1178–1184.
33. Cheung T H, Lo W K, Yim S F, Chan L K, Jeung M S, Chan C S, CheungAY, Chung T K and Wong Y F (2004). Epigenetic and genetic alteration of PTEN in cervical neoplasm. Gynecol. Oncol 93, 621-627.
34. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman J G, Jen J, Isaacs W B, Bova G S and Sidransky D (1997). Frequent inactivation of PTEN/MMAC1 inprimary prostate cancer. Cancer Res, 57, 4997-5000.
35. Mutter G L, Lin M C, Fitzgerald J T, Kum J B, Baak J P, Lees J A, Weng L P and Eng C (2000). Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst., 92, 924–930.
36. Poetsch M, Dittberner T and Woenckhaus C (2001) PTEN/MMAC1 in malignant melanoma and its importance for tumor progression. Cancer Genet Cytogenet 125, 21–26.
37. Dahia P L M, Aguiar R C, Alberta J, Kum J B, Caron S, Sill H, Marsh D J, Ritz J, Freedman A, Stiles C and Eng C (1999). PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum Mol Genet, 8, 185–193.
38. Perren A, Weng L P, Boag A H, Ziebold U, Thakore K, Dahia P L, Komminoth P, Lees J A, Mulligan L M, Mutter G L and Eng C (1999). Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155, 1253–1260.
39. Yang H J, Liu V S W, Wang Y, Tsang P C K and Ngan HY S (2006). Differential DNAmethylation profiles in gynecological cancers and correlation with clinic-pathological data. BMC Cancer 6, 212.
40. Huang J and Kontos C D (2002). PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects. J. biol. Chem., 277, 10760–10766.
41. Kandel E S, Skeen J, Majewski N, Di Cristofano A, Pandolfi P P, Feliciano C S, Gartel A and Hay N (2002). Activation of Akt/protein kinase B overcomes a G (2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol., 22, 7831-7841.
42. Lee J S, Choi Y D, Lee J H, Nam J H, Choi C, Lee M C, Park C S, Kim H S and Min K W (2006). Expression of PTEN in the progression of cervical neoplasia and its relation to tumor behaviour and angiogenesis in invasive squamous cell carcinoma. J. Sug. Oncol. 93, 233-240.